Violation Of Januvia Patents Is Different From Other Cases, Says Merck India Head
This article was originally published in The Pink Sheet Daily
Executive Summary
MSD’s India chief says he is surprised by the violation of sitagliptin patents and called for robust systems to protect drug patents. He maintained MSD will continue to create holistic approaches to disease management in India.